NEW YORK (GenomeWeb News) – Response Biomedical has filed a prospectus to sell 73,333,333 units at a price of C$.15 per unit for gross proceeds of around C$11 million (US$9.5 million).

Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will enable the holder to purchase one additional common share at a price of C$.25 for a period of 24 months from the closing date of the offering, which is expected on or around May 21, said Response Biomedical.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.